Schizophrenia: advances in pathophysiology, management, and precision medicine.

Biomarker identification and patient stratification are essential for advancing precision medicine in schizophrenia, a condition with significant biological heterogeneity.

• Why it matters: Current treatments are limited by the diverse biological underpinnings of schizophrenia, which hampers the development of targeted therapies and personalized care strategies.
• What they did: The study emphasizes the need to gather objective biomarkers and reframe schizophrenia through mechanism-based stratification, integrating biological characteristics into clinical practice.
• The result: This approach will enable more effective, individualized treatments and improve management outcomes, paving the way for future breakthroughs in schizophrenia therapy.